Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endonuclease IV (Endo IV), encoded by the nfo gene in Escherichia coli, is a vital DNA repair enzyme belonging to the Class II AP endonuclease family (UniProt P0A6B7). It plays a critical role in the base excision repair (BER) pathway by recognizing and cleaving the phosphodiester backbone at apurinic/apyrimidinic (AP) sites, which are common DNA lesions resulting from spontaneous hydrolysis or oxidative damage (PubMed: 2631424). Unlike the more abundant Exonuclease III, Endonuclease IV is specifically induced by oxidative stress and is capable of removing a variety of 3'-blocking groups, such as 3'-phosphoglycolate and 3'-phosphate, to facilitate DNA polymerase activity (PubMed: 2983314). Structurally, it is a TIM-barrel protein that utilizes a tri-zinc center to catalyze the hydrolysis of the DNA backbone (PDB: 1QTW). While not a primary human therapeutic target, it is investigated as an antimicrobial target to sensitize bacteria to DNA-damaging agents and oxidative stress (PubMed: 16439568). Inhibition of this enzyme can lead to the accumulation of lethal DNA breaks in bacterial cells, particularly when combined with other stressors. It serves as a model for understanding the repair of oxidative DNA damage across various species.
Endonuclease IV catalyzes the hydrolysis of the phosphodiester bond 5' to an abasic site, generating a 3'-hydroxyl group and a 5'-deoxyribose-5-phosphate (dRP) terminus (PubMed: 2631424).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endonuclease 4 (Endo IV) (Endo IV).